Pike M C, Kredich N M, Snyderman R
Proc Natl Acad Sci U S A. 1979 Jun;76(6):2922-6. doi: 10.1073/pnas.76.6.2922.
Chemotaxis by human monocytes has been shown to require methylation mediated by S-adenosyl-L-methionine(AdoMet), but the specific transmethylation reaction necessary for this function was not elucidated. In an attempt to define the methylation requirement for chemotaxis, we examined the effect of chemotactic agonists and antagonists on protein carboxy-O-methylation of protein and methylation of phospholipid in guinea pig macrophages. Chemotactic agents tested over a wide dose and time range produced no alteration in carboxy-O-methylation. However, these agents did produce an effect on the methylation of phosphatidylethanolamine by macrophages. AdoMet-mediated phospholipid methylation was inhibited by as much as 73% by chemotactic factors, and there was excellent correlation (r = 0.99) between their concentrations for producing half-maximal chemotactic responses and for inhibiting phospholipid methylation. The inhibition of methylation by chemotactic factors was observed at all incubation times and could not be explained by an increased turnover of membrane phospholipid. Neither the chemotaxis antagonist fPhe-Met nor the nonchemotactic tripeptide Met-Met-Met significantly depressed phospholipid methylation. Immune phagocytosis by macrophages similarly did not alter phospholipid methylation. The chemotactic factors produced no alteration in total macrophage phospholipid synthesis or in the phospholipid methylation in a nonchemotactic cell type. The formation of newly methylated derivatives of phosphatidylethanolamine in macrophages was decreased by a biologically active dose of chemotactic factor. These findings indicate that chemotactic factors are capable of altering the methylation of phosphatidylethanolamine in chemotactically responsive cells. The inhibition of phospholipid methylation by chemotactic factors may be necessary for the translation of a chemotactic signal on the surface of the cell into directional cell movement.
已表明人单核细胞的趋化性需要由S-腺苷-L-甲硫氨酸(AdoMet)介导的甲基化作用,但尚未阐明此功能所需的具体转甲基反应。为了确定趋化性对甲基化的需求,我们研究了趋化激动剂和拮抗剂对豚鼠巨噬细胞中蛋白质羧基-O-甲基化以及磷脂甲基化的影响。在很宽的剂量和时间范围内测试的趋化剂未引起羧基-O-甲基化的改变。然而,这些试剂确实对巨噬细胞中磷脂酰乙醇胺的甲基化产生了影响。趋化因子可使AdoMet介导的磷脂甲基化抑制高达73%,并且它们产生半数最大趋化反应的浓度与抑制磷脂甲基化的浓度之间存在极好的相关性(r = 0.99)。在所有孵育时间均观察到趋化因子对甲基化的抑制作用,且这不能用膜磷脂周转率的增加来解释。趋化拮抗剂fPhe-Met和非趋化性三肽Met-Met-Met均未显著降低磷脂甲基化。巨噬细胞的免疫吞噬作用同样未改变磷脂甲基化。趋化因子对巨噬细胞总磷脂合成或非趋化性细胞类型中的磷脂甲基化没有影响。具有生物活性剂量的趋化因子可降低巨噬细胞中磷脂酰乙醇胺新甲基化衍生物的形成。这些发现表明,趋化因子能够改变趋化反应性细胞中磷脂酰乙醇胺的甲基化。趋化因子对磷脂甲基化的抑制作用可能是将细胞表面的趋化信号转化为细胞定向运动所必需的。